Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | BLM | P54132 | 2/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.59 |
| ▸ | HTR2A | P28223 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | MPO | P05164 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.57 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.57 |
| ▸ | TNF | P01375 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | HTR6 | P50406 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29982303 | 1.00 | KDM4E (0.59) | KDM4EKMT2ALMNAMAPTTSHR | |
| Benzene SCHEMBL28112748 | 1.00 | KDM4E (0.59) | KDM4EKMT2ALMNAMAPTTSHR | |
| SCHEMBL1461102 | 1.00 | KDM4E (0.59) | KDM4EKMT2ALMNAMAPTTSHR | |
| SCHEMBL18029023 | 1.00 | KDM4E (0.59) | KDM4EKMT2ALMNAMAPTTSHR | |
| SCHEMBL4212844 | 0.95 | KDM4E (0.57) | KDM4EKMT2ALMNAMAPTTSHR | |
| SCHEMBL4212860 | 0.95 | KDM4E (0.57) | KDM4EKMT2ALMNAMAPTTSHR | |
| SCHEMBL4212849 | 0.93 | KDM4E (0.52) | KDM4EKMT2ALMNAMAPTTSHR | |
| SCHEMBL31369722 | 0.89 | KDM4E (0.56) | KDM4EKMT2ALMNAMAPTTSHR | |
| SCHEMBL6771825 | 0.88 | MTNR1A (0.59) | KDM4EKMT2ALMNAMAPTTSHR | |
| SCHEMBL31688533 | 0.87 | KMT2A (0.56) | KDM4EKMT2ALMNAMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118184756-A | Engineered Leptospira perfoliatum lectin mutant and application thereof | 浙江大学医学院附属第一医院(浙江省第一医院) | 2024-06-14 | — | — | CN | claimed |
| CN-114940979-B | Method for improving cation-pi interaction by utilizing genetic code expansion and application | 杭州嵌化合生医药科技有限公司 | 2024-01-23 | — | — | CN | claimed |
| CN-116836959-A | Enzyme composition for synthesizing neomycin derivative and application thereof | 山东大学 | 2023-10-03 | — | — | CN | claimed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | claimed |
| CN-114940979-A | Method for improving cation-pi interaction by genetic code expansion and application | 浙江大学 | 2022-08-26 | — | — | CN | claimed |
| US-20160331725-A1 | USE OF COMPOUNDS THAT ARE ABLE TO INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASE STATES ASSOCIATED WITH A REDUCED IGF-1 SERUM LEVEL IN HUMANS AND ANIMALS | VEIJLEN N.V. | 2016-11-17 | — | — | US | claimed |
| JP-4641942-B2 | — | — | 2011-03-02 | — | — | JP | claimed |
| US-20080194553-A1 | compounds that are capable of increasing the serum level of insulin-like growth factor 1 (IGF-1) for the preparation of a therapeutical composition,in the form of a food supplement, for the treatment of subjects suffering from serious fatigue and exhausting symptoms, burn-out and chronic fatigue syndrome | VEIJLEN N.V. (NL) | 2008-08-14 | — | — | US | claimed |
| EP-1670444-A2 | USE OF INDOLEACETIC ACID DERIVATIVES WHICH INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASES | Veijlen N.V. (AN) | 2006-06-21 | — | — | EP | claimed |
| WO-2005039546-A2 | USE OF INDOLEACETIC ACID DERIVATIVES WHICH INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASES | VEIJLEN N.V. (AN) | 2005-05-06 | — | — | WO | claimed |
| US-20240390508-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE-DRUG CONJUGATE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-11-28 | — | — | US | disclosed |
| US-20240229090-A1 | MODIFIED BACTERIA FOR PRODUCTION OF NITROAROMATICS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240229090-A1 | MODIFIED BACTERIA FOR PRODUCTION OF NITROAROMATICS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-07-11 | — | — | US | disclosed |
| EP-4389893-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE-DRUG CONJUGATE | Takeda Pharmaceutical Company Limited (JP) | 2024-06-26 | — | — | EP | disclosed |
| CN-118201966-A | Human transferrin receptor binding antibody-peptide conjugates | 肽梦想株式会社 | 2024-06-14 | — | — | CN | disclosed |
| EP-1175502-A4 | HALO- OR HYDROXY-SUBSTITUTED NOCATHIACIN ANTIBIOTICS | BRISTOL MYERS SQUIBB CO (US) | 2002-07-24 | — | — | EP | disclosed |
| EP-1175502-A1 | HALO- OR HYDROXY-SUBSTITUTED NOCATHIACIN ANTIBIOTICS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-01-30 | — | — | EP | disclosed |
| US-6287827-B1 | FERMENTATION OF NOCARDIA; ADMINISTERED TO TREAT DRUG OR ANTIBIOTIC RESISTANT GRAMPOSITIVE BACTERIAL INFECTIONS | BRISTOL-MYERS SQUIBB COMPANY | 2001-09-11 | — | — | US | disclosed |
| WO-2000068413-A1 | HALO- OR HYDROXY-SUBSTITUTED NOCATHIACIN ANTIBIOTICS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-11-16 | — | — | WO | disclosed |
| US-4110536-A | ANTIARRHYTHMIA | MILES LABORATORIES, INC. (US) | 1978-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240390508-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE-DRUG CONJUGATE | MUSK, TFRC, SLC7A1 | KDM4E 2530/4885KMT2A 3558/4885LMNA 2682/4885 |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | KDM4E 4463/4885KMT2A 3083/4885LMNA 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.